1-10 of 10
Ladislav Andera
Close
Sort by
Journal Articles

biomarker Driven Strategies for Targeted Elimination of Hypoxia Adapted Lymphoma Cells

Pavel Klener, Jr., Lenka Daumová, Dmitry Kazantsev, Ladislav Anděra, Jiří Petrák, Alexandra Dolníková, Nardjas Bettazová, Petra Kovaříková, Nicol Renešová, Liliana Tušková, Dana Sovilj, Marek Trněný, Magdalena Klanova, Ondrej Havránek
Journal: Blood
Blood (2023) 142 (Supplement 1): 4374.
https://doi.org/10.1182/blood-2023-182705
Published: 2023
Journal Articles

BCL-XL Blockage with A1155463 Significantly Increases Efficacy of Venetoclax in Mantle Cell Lymphoma in Vitro and In Vivo

Alexandra Dolníková, Dmitry Kazantsev, Diana Malarikova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Ladislav Andera, Marek Trněný, Pavel Klener, Jr.
Journal: Blood
Blood (2022) 140 (Supplement 1): 6383–6384.
https://doi.org/10.1182/blood-2022-170109
Published: 2022
Journal Articles

Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BH3-Mimetics in Experimental Models of Relapsed/Refractory Mantle Cell Lymphoma

Diana Malarikova, Radek Jorda, Alexandra Dolníková, Ondrej Havranek, Eva Pokorna, Dmitry Kazantsev, Dana Sovilj, Karel Helman, Magdalena Klanova, Ladislav Andera, Miroslav Strnad, David Chiron, Marek Trneny, Pavel Klener, Jr.
Journal: Blood
Blood (2022) 140 (Supplement 1): 5996–5997.
https://doi.org/10.1182/blood-2022-168617
Published: 2022
Journal Articles

Co-Targeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Refractory Mantle Cell Lymphoma with Complex Karyotype Changes

Pavel Klener, Jr., Marek Trněný, Ladislav Andera, MSc, PhD, Zuzana Nahacka, MSc, Magdalena Klanova, MD PhD, Jana Karolova, MD, Michael Svaton, MD, Ondrej Havranek, MDPhD, Jan Soukup, MD, Zuzana Zemanova, PhD, Diana Tuskova, MD, Eva Pokorna, Kristina Forsterova, MSc, PhD, Petra Vockova, MD, Eva Fronkova, MD PhD, Dana Prukova, Ing, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 42.
https://doi.org/10.1182/blood-2018-99-112437
Published: 2018
Journal Articles

MCL1 Targeting Agent Homoharringtonine Exerts Strong Cytotoxicity Towards Diffuse Large B-Cell Lymphoma (DLBCL) Cells and Synergizes with BCL2 Targeting Agent ABT199 in Eliminating BCL2-Positive DLBCL Cells

Magdalena Klanova, MD, Ladislav Andera, M.Sc. PhD, Jan Soukup, MDPhD, Brazina Jan, M.Sc., Jan Svadlenka, M.Sc., Simona Benesova, M.Sc., Dana Prukova, M.Sc. PhD, Dana Vejmelkova, M.Sc., Radek Jaksa, MD, Karel Helman, PhD, Petra Vockova, MD, Lucie Lateckova, MD, Jan Molinsky, MD PhD, Bokang Maswabi, MD, Mahmudul Alam, PhD, Roman Kodet, Prof. MD, Marek Trneny, Pavel Klener, MD, PhD
Journal: Blood
Blood (2014) 124 (21): 3645.
https://doi.org/10.1182/blood.V124.21.3645.3645
Published: 2014
Journal Articles

Roscovitine Sensitizes Leukemia and Lymphoma Cells to TRAIL-Induced Apoptosis and Enhances Cell-Mediated Cytotoxicity

Jan Molinsky, Marie Markova, Magdalena Klanova, Michal Koc, Lenka Beranova, Ladislav Andera, Zdenka Ludvikova, Martina Bohmova, Zdenka Gasova, Marek Trneny, Emanuel Necas, Jan Zivny, Pavel Klener
Journal: Blood
Blood (2010) 116 (21): 596.
https://doi.org/10.1182/blood.V116.21.596.596
Published: 2010
Journal Articles

Upregulation of Caspase 10 Contributes to Acquired Resistance of Acute T-Lymphoblastic Leukemia Cells to Proapoptotic Cytokine TRAIL.

Pavel Klener, Jr., Jan Molinsky, Marie Markova, Sergiu Leahomschi, Tereza Simonova, Ladislav Andera, Emanuel Necas, Jan Zivny
Journal: Blood
Blood (2009) 114 (22): 3790.
https://doi.org/10.1182/blood.V114.22.3790.3790
Published: 2009
Journal Articles

Acquired Resistance to Tumor Necrosis Factor-Related Apoptosis- Inducing Ligand (TRAIL): Histone Deacetylase Inhibitors Resensitize TRAIL-Resistant Jurkat Acute Lymphocytic Leukemia Cells

Pavel Klener, Jr., Jan Molinsky, Tereza Simonova, Emanuel Necas, Ladislav Andera, Jan Zivny
Journal: Blood
Blood (2008) 112 (11): 5032.
https://doi.org/10.1182/blood.V112.11.5032.5032
Published: 2008
Journal Articles

Proteomic and mRNA Expression Chip Analysis of Acquired TRAIL-Resistance in Human HL60 Myeloid Leukemia Cells.

Jan Zivny, MD, PhD, Pavel Klener, MD, Ondrej Toman, PhD, Petr Halada, PhD, Robert Ivanek, Tereza Simonova, Ladislav Andera, PhD, Emanuel Necas, MD,DrSc, Jiri Petrak, PhD
Journal: Blood
Blood (2007) 110 (11): 4155.
https://doi.org/10.1182/blood.V110.11.4155.4155
Published: 2007
Journal Articles

Genome-Wide and Functional Analysis of Acquired Resistance to TRAIL/APO2l Mediated Apoptosis of Leukemia Cell Lines.

Jan Zivny, MD,PhD, Pavel Klener, MD, Pavel Prochazka, MD, Sergiu Laehomschi, Ales Vicha, MD,PhD, Tomas Eckschlager, MD,PhD, Ladislav Andera, PhD, Emanuel Necas, MD,PhD
Journal: Blood
Blood (2006) 108 (11): 4385.
https://doi.org/10.1182/blood.V108.11.4385.4385
Published: 2006